Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

New treatments, particularly second‐line options, are needed to improve outcomes for patients with recurrent/metastatic cervical cancer (r/mCC). Tisotumab vedotin (TV) is an antibody–drug conjugate directed to tissue factor, a transmembrane protein commonly expressed in cancer cells, to deliver cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonemori, Kan, Kuboki, Yasutoshi, Hasegawa, Kosei, Iwata, Takashi, Kato, Hidenori, Takehara, Kazuhiro, Hirashima, Yasuyuki, Kato, Hisamori, Passey, Chaitali, Buchbjerg, Jeppe Klint, Harris, Jeffrey R., Andreassen, Camilla Mondrup, Nicacio, Leonardo, Soumaoro, Ibrahima, Fujiwara, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357646/
https://www.ncbi.nlm.nih.gov/pubmed/35633184
http://dx.doi.org/10.1111/cas.15443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357646/
https://www.ncbi.nlm.nih.gov/pubmed/35633184
http://dx.doi.org/10.1111/cas.15443

Ejemplares similares